Bioelectronics Corp (BIEL)

[gimmee greenbacks]

You crack me up:

" problem is, efficacy in WOMEN was not the primary endpoint in that study. "

Primary endpoint, secondary endpoint, miscellaneous finding.. semantics, who cares ? The bottom line is
the FDA cannot contradict it's own finding.of significant benefit for women and in so doing had implicitly
endorsed ALLAY. FACT.



" The FDA hates cherry picking. they usually reject a study that's been cherry-picked, telling the company to run a new trial. BIEL better be prepared for that and start it ASAP. "

Give me a break.

$BIEL$$$